Key Takeaway: UroGen reported a revenue of $50.4 million for ZUSDURI in Q2 2026, marking a significant 73% growth compared to the previous quarter. The company anticipates a new U.S. patent that will protect ZUSDURI and UGN-103 until July 2044. Additionally, UGN-103 is progressing towards its NDA submission.
Price reaction · baseline $39.92 (2026-08-04 close) · hit pre-market · clean, no other URGN news in the window
day 0 close · peak
+16.3%
day 1
+14.2%
day 3
+16%
Market Sentiment Analysis
POSITIVE FACTORS
ZUSDURI generated $50.4 million in revenue.
73% quarter-over-quarter growth in revenue.
New U.S. patent expected to provide protection until July 2044.
Advancement of pipeline with UGN-103 on track for NDA submission.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+176%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Lead asset
UGN-101 instillations
Phase 3 · Carcinoma, Transitional Cell
Full Press Release Details
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103 Continued advancement of pipeline, with UGN-103 on track for NDA submission
Frequently Asked Questions
What revenue did UroGen report for ZUSDURI in Q2 2026?
UroGen reported $50.4 million in revenue for ZUSDURI in Q2 2026.
What was the growth percentage for ZUSDURI revenue?
ZUSDURI revenue grew by 73% quarter-over-quarter.
When is the new U.S. patent for ZUSDURI expected?
The new U.S. patent is expected to provide protection until July 2044.